Kassem Asmaa F, Sediek Ashraf A, Omran Mervat M, Foda Doaa S, Al-Ashmawy Aisha A K
Chemistry of Natural and Microbial Products Department, National Research Centre Dokki 12622 Cairo Egypt.
Chemical Industries Institute, National Research Centre Dokki 12622 Cairo Egypt.
RSC Adv. 2024 Oct 7;14(43):31607-31623. doi: 10.1039/d4ra06146b. eCollection 2024 Oct 1.
Herein, the molecular hybridization drug discovery approach was used in the design and synthesis of twelve novel pyridine-2,3-dihydrothiazole hybrids (2a,b-5a,b and 13a,b-14a,b) and fourteen pyridine-thiazolidin-4-one hybrids (6a,b-12a,b) as anti-proliferative analogues targeting CDK2 and GSK3β kinase inhibition. Almost all of the newly synthesized hybrids, including their precursors (1a,b), were evaluated for their anti-proliferative activity against three human cancer cell lines-MCF-7, HepG2 and HEp-2-as well as normal Vero cell lines. Both compounds 1a (pyridine-thiourea precursor) and 8a (pyridine-5-acetyl-thiazolidin-4-one hybrid) exhibited excellent anti-proliferative activity against HEp-2 (IC = 7.5 μg mL, 5.9 μg mL, respectively). Additionally, 13a (pyridine-5-(-tolyldiazenyl-2,3-dihydrothiazole)) hybrid demonstrated excellent anti-proliferative activity against HepG2 (IC = 9.5 μg mL), with an acceptable safety profile against Vero (<45% inhibition at 100 μg mL) in the cases of 8a and 13a alone. The three promising anti-proliferative hybrids (1a, 8a, 13a) were selected for the assessment of their inhibitory kinase activity against CDK2/GSK3β using roscovitine (IC = 0.88 μg mL) and CHIR-99021 (IC = 0.07 μg mL) as references, respectively. Compound 13a was the most potent dual CDK2/GSK3β inhibitor (IC = 0.396 μg mL, 0.118 μg mL, respectively) followed by 8a (IC = 0.675 μg mL, 0.134 μg mL, respectively), and the weakest was 1a. To elucidate the mechanism of the most potent anti-proliferative 13a hybrid, further cell cycle analysis was performed revealing that it caused G1 cell cycle arrest and induced apoptosis. Moreover, it resulted in an increase in Bax and caspase-3 with a decrease in Bcl-2 levels in HepG2 cells compared with untreated cells. Finally, drug likeness/ADME prediction for the three potent compounds as well as a molecular docking simulation study were conducted in order to explore the binding affinity and interactions in the binding site of each enzyme, which inspired their usage as anti-proliferative leads for further modification.
在此,分子杂交药物发现方法被用于设计和合成12种新型吡啶 - 2,3 - 二氢噻唑杂化物(2a,b - 5a,b和13a,b - 14a,b)以及14种吡啶 - 噻唑烷 - 4 - 酮杂化物(6a,b - 12a,b),作为靶向CDK2和GSK3β激酶抑制的抗增殖类似物。几乎所有新合成的杂化物及其前体(1a,b)都针对三种人类癌细胞系——MCF - 7、HepG2和HEp - 2以及正常Vero细胞系评估了它们的抗增殖活性。化合物1a(吡啶 - 硫脲前体)和8a(吡啶 - 5 - 乙酰 - 噻唑烷 - 4 - 酮杂化物)对HEp - 2均表现出优异的抗增殖活性(IC分别为7.5 μg/mL、5.9 μg/mL)。此外,13a(吡啶 - 5 -(对甲苯基重氮基 - 2,3 - 二氢噻唑))杂化物对HepG2表现出优异的抗增殖活性(IC = 9.5 μg/mL),就8a和13a单独的情况而言,对Vero细胞具有可接受的安全性(在100 μg/mL时抑制率<45%)。选择三种有前景的抗增殖杂化物(1a、8a、13a),分别以roscovitine(IC = 0.88 μg/mL)和CHIR - 99021(IC = 0.07 μg/mL)作为参考,评估它们对CDK2/GSK3β的抑制激酶活性。化合物13a是最有效的双重CDK2/GSK3β抑制剂(IC分别为0.396 μg/mL、0.118 μg/mL),其次是8a(IC分别为0.675 μg/mL、0.134 μg/mL),最弱的是1a。为了阐明最有效的抗增殖杂化物13a的作用机制,进行了进一步的细胞周期分析,结果表明它导致G1期细胞周期停滞并诱导凋亡。此外,与未处理的细胞相比,它导致HepG2细胞中Bax和caspase - 3增加,Bcl - 2水平降低。最后,对这三种有效化合物进行了药物相似性/药物代谢动力学预测以及分子对接模拟研究,以探索它们在每种酶结合位点的结合亲和力和相互作用,这为它们作为抗增殖先导物进行进一步修饰提供了依据。